NASDAQ:MYOS - MYOS Co. common stock Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.32 -0.02 (-1.49 %)
(As of 07/18/2018 04:00 PM ET)
Previous Close$1.34
Today's Range$1.31 - $1.36
52-Week Range$1.03 - $2.50
Volume93,100 shs
Average Volume165,327 shs
Market Capitalization$9.19 million
P/E Ratio-1.91
Dividend YieldN/A
MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.

Receive MYOS News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio4.93
Quick Ratio0.89


Trailing P/E Ratio-1.91
Forward P/E Ratio-3.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$530,000.00
Price / Sales16.59
Cash FlowN/A
Price / CashN/A
Book Value$0.69 per share
Price / Book1.91


EPS (Most Recent Fiscal Year)($0.69)
Net Income$-4,050,000.00
Net Margins-959.35%
Return on Equity-95.44%
Return on Assets-87.00%


Outstanding Shares6,660,000
Market Cap$9.19

The Truth About Cryptocurrencies

MYOS Co. common stock (NASDAQ:MYOS) Frequently Asked Questions

What is MYOS Co. common stock's stock symbol?

MYOS Co. common stock trades on the NASDAQ under the ticker symbol "MYOS."

How were MYOS Co. common stock's earnings last quarter?

MYOS Co. common stock (NASDAQ:MYOS) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.11. The firm earned $0.06 million during the quarter, compared to analysts' expectations of $0.18 million. MYOS Co. common stock had a negative net margin of 959.35% and a negative return on equity of 95.44%. View MYOS Co. common stock's Earnings History.

When is MYOS Co. common stock's next earnings date?

MYOS Co. common stock is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for MYOS Co. common stock.

What is the consensus analysts' recommendation for MYOS Co. common stock?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MYOS Co. common stock in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of MYOS Co. common stock's key competitors?

Who are MYOS Co. common stock's key executives?

MYOS Co. common stock's management team includes the folowing people:
  • Mr. Joseph Mannello, CEO & Director (Age 60)
  • Mr. Ren Ren, Global Chairman (Age 56)
  • Mr. Joseph DiPietro, Controller
  • Mr. Magshoud Dariani, Chief Technology Officer
  • Mr. Dominick Commesso, Exec. VP of Sales and Marketing

Has MYOS Co. common stock been receiving favorable news coverage?

Media stories about MYOS stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. MYOS Co. common stock earned a news sentiment score of 0.07 on Accern's scale. They also assigned media headlines about the company an impact score of 45.56 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of MYOS Co. common stock?

Shares of MYOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MYOS Co. common stock's stock price today?

One share of MYOS stock can currently be purchased for approximately $1.32.

How big of a company is MYOS Co. common stock?

MYOS Co. common stock has a market capitalization of $9.19 million and generates $530,000.00 in revenue each year. The company earns $-4,050,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. MYOS Co. common stock employs 10 workers across the globe.

How can I contact MYOS Co. common stock?

MYOS Co. common stock's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 973-509-0444 or via email at [email protected]

MarketBeat Community Rating for MYOS Co. common stock (NASDAQ MYOS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about MYOS Co. common stock and other stocks. Vote "Outperform" if you believe MYOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.